Woman Leaves Big Gift

A philanthropist who lost her battle with non-Hodgkin's Lymphoma lost her battle, but left a big gift:

"When Eileen Fulford died last year in Charlottetown after a two and a half-year battle with non-Hodgkin's lymphoma, she left a remarkable legacy as a volunteer, teacher, nurse, philanthropist and a top golfer. She also left something of a surprise for her family.

Ms. Fulford, who was 64, bequeathed $1.5-million to Charlottetown’s Queen Elizabeth Hospital, one of the largest individual gifts in the hospital’s history.

True to her nature, she didn’t want any personal recognition. Instead she made the donation in the name of her parents, Joseph and Eileen McMillan, whose names will be on a new ambulatory care centre. Dr. McMillan, who died in 1972, was a renowned surgeon who founded a local clinic and won the Canadian Medical Association’s first Medal of Service in 1946. Ms. McMillan, who passed away in 2007, was one of the province’s first dieticians."

Read More: http://www.ctv.ca/generic/generated/static/business/article1787961.html

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap